Trump's New Drug Pricing Order Promises Massive Savings, But Lacks Details

US Pharma freaks out as Trump orders drug price cuts

The executive order claims to slash prescription costs and shake up Big Pharma, but key details , including coverage and timeline, remain vague. Supporters say it's a welcome blow to pharmaceutical cartels, while critics warn of legal risks, market disruption, and political posturing ahead of 2026 price changes.

Today (Monday) at 9:00 A.M., President Donald Trump will sign an executive order designed to dramatically lower prescription drug prices in the United States, reviving a contentious policy from his first term.

The initiative seeks to align U.S. drug costs with those in other high-income nations, potentially cutting prices by 30% to 80%, according to administration claims. Announced via Truth Social on May 11, the move targets an issue that resonates deeply with Americans grappling with soaring healthcare costs, but its path to implementation faces significant hurdles.

The executive order resurrects Trump’s “most favored nation” (MFN) pricing model, first proposed in 2020, which would peg U.S. drug prices to the lowest rates paid by other developed countries. Back then, the policy, focused on Medicare Part B drugs, was projected to save $85 billion over seven years but was blocked by federal courts and later rescinded by the Biden administration in 2021.

Details of the new order remain sparse, leaving unclear which drugs or programs, Medicare, Medicaid, or private insurance, it will cover. Trump has claimed the policy could save “trillions of dollars,” though the basis for this figure is unspecified.

The move comes as Americans are increasingly frustrated by the price of drugs. The U.S. pays two to three times more for many medications than other wealthy nations, a gap Trump has long vowed to close. On April 15, 2025, he signed a related executive order to enhance Medicare’s negotiation program and encourage drug importation, in hwat could well be a realted development.

Public reaction, particularly among Trump’s supporters, has been enthusiastic. Posts on X praise the order as a strike against pharmaceutical “cartels,” with some claiming it could save families billions.

However, the pharmaceutical industry, led by groups like PhRMA, has pushed back sharply. PhRMA president Stephen Ubl called the policy a “Foreign First Pricing scheme” that risks stifling innovation and disrupting healthcare markets. Analysts warn that legal challenges, similar to those that derailed the 2020 effort, could again delay or dismantle the initiative. The rulemaking process, overseen by the Department of Health and Human Services, is expected to take months, if not years.

Complicating matters, Trump’s simultaneous advocacy for pharmaceutical tariffs could undermine price reductions by risking drug shortages or cost increases. Democrats, including DNC spokesperson Alex Floyd, have criticized Trump’s broader healthcare record, pointing to his January 20, 2025, reversal of Biden-era drug pricing reforms as evidence of corporate favoritism.

Biden’s Inflation Reduction Act of 2022, which empowered Medicare to negotiate prices for high-cost drugs, achieved up to 79% price cuts for 10 medications, set to take effect in 2026. Trump’s order does not directly alter these reforms but charts a different course.

For consumers, the promise of lower drug prices is tantalizing, particularly for seniors on fixed incomes. Yet, without clear details or a quick path to implementation, the order’s immediate impact remains uncertain.